KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Non-Current Liabilities: 2018-2025

Historic Other Non-Current Liabilities for Castle Biosciences (CSTL) over the last 2 years, with Sep 2025 value amounting to $1.5 million.

  • Castle Biosciences' Other Non-Current Liabilities was N/A to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year change of. This contributed to the annual value of $25,000 for FY2023, which is 72.22% down from last year.
  • Castle Biosciences' Other Non-Current Liabilities amounted to $1.5 million in Q3 2025, which was down 0.00% from $1.5 million recorded in Q2 2025.
  • Castle Biosciences' Other Non-Current Liabilities' 5-year high stood at $18.3 million during Q4 2021, with a 5-year trough of $16,000 in Q1 2024.
  • Its 3-year average for Other Non-Current Liabilities is $454,143, with a median of $47,000 in 2023.
  • Per our database at Business Quant, Castle Biosciences' Other Non-Current Liabilities soared by 1,682.36% in 2021 and then tumbled by 99.51% in 2022.
  • Castle Biosciences' Other Non-Current Liabilities (Quarterly) stood at $18.3 million in 2021, then tumbled by 99.51% to $90,000 in 2022, then plummeted by 72.22% to $25,000 in 2023, then crashed by 70.91% to $16,000 in 2024, then reached $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.5 million for Q2 2025, and $16,000 during Q1 2024.